During the last session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s traded shares were 0.37 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $9.18, reflecting an intraday gain of 0.88% or $0.08. The 52-week high for the PHAT share is $17.02, that puts it down -85.4 from that peak though still a striking 33.88% gain since the share price plummeted to a 52-week low of $6.07. The company’s market capitalization is $536.85M, and the average trade volume was 880.16K shares over the past three months.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Phathom Pharmaceuticals Inc (PHAT) registered a 0.88% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.88% in intraday trading to $9.18, hitting a weekly high. The stock’s 5-day price performance is 2.34%, and it has moved by -16.92% in 30 days. Based on these gigs, the overall price performance for the year is -10.09%.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Statistics show that Phathom Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Phathom Pharmaceuticals Inc (PHAT) shares have gone up 2.00% during the last six months, with a year-to-date growth rate less than the industry average at -66.80% against 12.90. In the rating firms’ projections, revenue will increase 6,470.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.05M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 6.07M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -137.06%. While earnings are projected to return -11.84% in 2024.
PHAT Dividends
Phathom Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
